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Abstract
Background: Attention deficit hyperactivity disorder is a heterogeneous disorder, associated with deficits in motivation (e.g., 
delay aversion) and cognition. Methylphenidate is recommended as a first line treatment for attention deficit hyperactivity 
disorder symptoms, but little is known about its nonacute effects on motivational and cognitive deficits, particularly in adults 
with attention deficit hyperactivity disorder.
Methods: We utilized a prospective, non-randomized, non-blinded, 6-week follow-up design with 42 initially stimulant 
medication-naïve adult patients with moderate to severe attention deficit hyperactivity disorder, and 42 age- and parental 
education-matched healthy controls. Delay aversion and executive functioning were assessed with 2 questionnaires and 5 
performance-based tests.
Results: At baseline, patients and controls differed significantly on performance-based measures (moderate to large effect 
sizes), and self-report of delay aversion and executive functioning (very large effect sizes). Treatment with methylphenidate 
medication (mean dose 65.54 mg/d, SD = 10.39) was not associated with improvements in performance-based measures of 
delay aversion and executive functioning compared to controls, although improvements in self-report executive functioning 
and delay aversion were found. Self-reported delay aversion was most consistently associated with ADHD symptomatology 
at baseline and after medication.
Conclusion: Methylphenidate treatment does not have an effect on performance-based measures of delay aversion and 
executive functioning, but may have significant effects on self-reported delay aversion and executive functioning. The latter 
finding should be interpreted cautiously, given the subjective nature of these measures and design limitations. Self-reported 
delay aversion is most consistently associated with attention deficit hyperactivity disorder symptomatology.
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Introduction
Attention deficit hyperactivity disorder (ADHD) is a common 
neurodevelopmental disorder with a prevalence of around 
2.5% in adults (Simon et  al., 2009). Recently, dual pathway 
(Sonuga-Barke, 2002, 2003), and multiple pathway models 
(Sonuga-Barke et al., 2010) of ADHD have been proposed based 
on evidence of partially dissociable patterns of deficits in dis-
tinct neuropsychological domains in individuals with ADHD 
(e.g., Solanto et  al., 2001; Sonuga-Barke et  al., 2010; Coghill 
et  al., 2014; Thorell et  al., 2016; but see Lambek et  al., 2017). 
Two domains thought to be particularly important are execu-
tive functioning (EF) and delay aversion (DA) (Sonuga-Barke, 
2002, 2003).
DA is expressed as a number of different behaviors, theorized 
to be motivated by the desire to escape or avoid delay. It is pos-
tulated to be rooted in biologically based alterations in reward 
mechanisms, which, conditioned over time by the child’s early 
experiences, result in delay experiences acquiring negative affec-
tive qualities. DA is expressed differently depending on whether 
delay can be avoided or not. In situations where delay can be 
reduced (i.e., where there is a choice), delay-averse individuals 
will tend to choose the more immediate option even if it means 
losing reward (Sonuga-Barke, 2002, 2003). Preference for “smaller 
sooner” over “larger later” rewards is regarded by many as the 
hallmark of DA (Bitsakou et al., 2009) and is supported by recent 
meta-analyses (Patros et  al., 2016). However, where delay can-
not be escaped, other activity and attention-based responses are 
required to reduce the perception of time in passing. For instance, 
on the Delay Frustration Test, sensitivity to interruption by unex-
pected and unavoidable periods of delay, where DA is expressed 
as an increase in frustration-related responding, was associated 
with higher levels of ADHD symptomatology in a nonclinical adult 
sample (Bitsakou et al., 2006). The Quick Delay Questionnaire, a 
self-report questionnaire concerning DA that includes items 
relating to both choice and nonchoice situations, differentiates 
between adults with ADHD and healthy controls (Clare et al., 2010) 
and to an extent clinical controls (Thorell et al., 2016).
EF deficits have long been associated with ADHD. Robust group 
differences between adults with ADHD and controls have been 
found in domains such as inhibitory control (Lijffijt et al., 2005; 
Mowinckel et al., 2015), working memory (Alderson et al., 2013), 
and planning/problem-solving (e.g., Chamberlain et  al., 2011; 
Tucha et al., 2011). Questionnaires like the BRIEF-A (Roth et al., 
2005) reveal robust self-reported EF deficits in ADHD. However, the 
overlap of performance-based tests and self-report assessments 
has been found to be nonsignificant (Biederman et al., 2008, 2015).
Cognitive Effects of Pharmacological Treatment 
in ADHD
Methylphenidate, a dopamine reuptake inhibitor, is recom-
mended as a first line treatment for adult ADHD (Bushe et al., 
2016). A  recent meta-analysis reported positive, small- to 
medium-sized effects on response inhibition and working mem-
ory (Tamminga et  al., 2016); however, evidence came mainly 
from acute administration studies. Positive effects of acute 
methylphenidate have also been found on adult ADHD plan-
ning skills (Chamberlain et al., 2011). Adult studies with active 
treatment periods of 1 to at least 10 weeks (Bouffard et al., 2003; 
Boonstra et al., 2005; Fallu et al., 2006; Tucha et al., 2006; Ni et al., 
2013, 2016; Bron et al., 2014; Biederman et al., 2015; Skirrow et al., 
2015; Goodman et al., 2017) and a single open-label study of up 
to 52 weeks (Ginsberg et al., 2012) have found positive effects on 
some aspects of attention; mixed findings with regards to work-
ing memory, response inhibition, and planning; and no effects 
on spatial span or forward digit span. Of 2 nonacute methylphe-
nidate studies of delay-related behaviors, one adult study found 
positive effects of 2 weeks of methylphenidate on delay dis-
counting (Crunelle et al., 2014), whereas no effects of 6 months 
of methylphenidate on DA was found in children (Morell and 
Expósito, 2017).
We undertook a prospective study to investigate the effect 
of 6 weeks of methylphenidate treatment on cognitive and 
motivational deficits in adults with ADHD. Our aims were first 
to examine whether methylphenidate treatment is associated 
with improvements in DA and EF and second, to investigate the 
association between these functions and ADHD symptomatol-
ogy. We hypothesized that (1) at pretreatment, patients would 
demonstrate deficits in both DA and EF, and (2) after 6 weeks 
of medication adults with ADHD would, compared with con-
trols, show significant improvements in DA and EF; further, that 
changes in symptoms would be associated with changes in DA 
and EF.
Methods
The project was undertaken in accordance with the Helsinki 
Declaration and approved by the Ethical Committee of 
the Capital Region Copenhagen (registration: H-15001438). 
Informed consent was obtained from all participants. 
Participants were compensated with a gift card/payment of 
€100 per testing day.
Significance Statement
Methylphenidate is effective at treating the symptoms of adults with ADHD. Acute studies have found that methylphenidate 
also has positive, significant effects on cognitive functioning. Here we demonstrated that adult ADHD was associated with both 
self-reported and objective measures of executive control and delay aversion. Furthermore, 6 weeks of methylphenidate treat-
ment in adults was associated with improvements in both executive functioning and motivation, but these were limited only to 
subjective self-report and not found with objective tasks. Given the lack of blinding of treatment exposure, the association with 
subjective reports may be limited to changed perceptions rather than actual cognitive improvements.
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Participants
ADHD Patients
Stimulant medication-naïve adult patients with a primary diag-
nosis of disturbance of activity and attention (F90.0) or attention 
deficit disorder without hyperactivity (F98.8) according to ICD-10 
criteria (World Health Organization, 1992) were recruited from 
the Adult ADHD Clinic at the Copenhagen University Hospital, 
Glostrup. Diagnosis at the ADHD clinic was undertaken in 
accordance with clinical guidelines (Sundhedsstyrelsen, 2015) 
and based on in-depth clinical interviews, including the DIVA 
2.0 (Pettersson et al., 2015) interview with the patient, and wher-
ever possible, a significant other; BRIEF-A questionnaire (Roth 
et  al., 2005); the WHO Adult ADHD Self-Report Scale (ASRS) 
(Kessler et  al., 2005); and additional testing (e.g., intelligence 
tests) as required. Inclusion criteria for all participants were age 
18 to 45 years, legally competent, fluent in Danish, and fulfilled 
DSM-5 criteria of ADHD (ensured by checking patients’ journal 
information, particularly DIVA 2.0 responses and clinical his-
tory). Exclusion criteria were: primary neurological or psychiatric 
diagnosis other than ADHD; confirmed diagnosis of other neu-
rodevelopmental disorder including dyslexia; earlier diagnosis of 
severe depression; current suicidal tendencies; treatment with 
psychotropic drugs in the last 4 weeks, or with MAO-inhibitors in 
the last 2 weeks; treatment at any time with ADHD medication; 
substance abuse daily during the last 3  months and/or ongo-
ing substance abuse; head injury ever with >5 minutes loss of 
consciousness; pregnancy; red-green color-blindness; need for 
“complex treatment”; and physical disease relevant for medica-
tion (e.g., cardiac disease). Absence of other primary psychiatric 
diagnoses was confirmed after completion of diagnostic screen-
ing interview, the Mini International Neuropsychiatric Interview 
5.0 (MINI) (Sheehan et  al., 1998). ADHD symptomatology was 
assessed with the ADHD Investigator Symptom Rating Scale 
(AISRS) (Spencer et al., 2010) and the ASRS (Kessler et al., 2005).
Healthy Controls
Controls were recruited from the internet site http://www.for-
soegsperson.dk/ and matched at the group level on age, gender, 
and parental educational level. Exclusion criteria were: neu-
rological, psychiatric, or neurodevelopmental diagnosis ever 
(mild/moderate depression/anxiety were not exclusion crite-
ria); treatment with psychotropic drugs in the last 4 weeks, or 
with MAO-inhibitors in the last 2 weeks; treatment at any time 
with ADHD medication; substance abuse daily during the last 
3  months and/or ongoing substance abuse; head injury ever 
with >5 minutes loss of consciousness; pregnancy; and red-
green color-blindness. A total of 42 controls with a full baseline 
dataset were recruited, 38 of whom also completed follow-up 
testing. Controls undertook the same assessment as patients.
Design
The study was a prospective, nonrandomized, nonblinded, 
6-week follow-up study; a placebo arm for patients was not 
included. A healthy control group was included at both assess-
ment points in an attempt to control for retest effects. Patients’ 
medication commenced as soon as possible after baseline test-
ing; assessments of the participants were carried out on average 
6.7 weeks (SD = 1.0) apart.
Medication Procedure
All patients were treated with a tool compound, methylphe-
nidate, according to their clinical need (i.e., with individual 
titration). Treatment was initiated at a dose of 18  mg/d and 
increased in increments of 18 mg/d at 1-week intervals (mini-
mum) until an optimal dose was reached with regards to 
ADHD symptoms and any side-effects. Judgement of medica-
tion effects and monitoring of side-effects were undertaken 
in weekly telephone consultations by the project psychiatrist 
(J.L.S.). A  clinical appointment was undertaken 3 weeks after 
baseline, including a physical examination. A number of 37 of 38 
patients were treated with Concerta, an extended-release tablet 
for once-a-day oral administration of methylphenidate. A stable 
“end-point” dosage was taken for at least 2 weeks before fol-
low-up testing. Because of high sensitivity to methylphenidate, 
one patient was treated with the shorter duration methylpheni-
date, Medikenet CR. Final dosages of methylphenidate were 36 
to 108 mg/d (M = 65.54 mg, SD = 10.39). All patients had positive 
tests for plasma methylphenidate at follow-up, showing medi-
cation compliance. Controls did not receive medication.
Test Procedure
All neuropsychological assessments were undertaken by a 
licensed specialist in neuropsychology (A.M.L.) or by master’s-
level students who received training and supervision from this 
specialist. After baseline testing, 3 patients were excluded, each 
for differing reasons, despite having valid baseline data (i.e., 
complex case requirements; uncorrected hearing loss prevent-
ing EEG investigations in a parallel part of the project; suspected 
allergic reaction to methylphenidate), and 1 dropped out, such 
that 38 of the 42 patients (90.5%) tested at baseline had follow-
up data available for analysis.
Measures
Psychopathology
Psychopathology was assessed using 4 measures. The MINI 5.0 
(Sheehan et al., 1998) is a short, structured interview for psychi-
atric disorders. The Clinical Global Impression scale (Guy, 1976) 
is a clinician rated, 7-point scale for assessment of ADHD illness 
severity. The ASRS (Kessler et al., 2005) is an 18-item, self-report 
screening scale of adult ADHD DSM-IV criterion A  symptoms. 
Lastly, the AISRS (Spencer et  al., 2010) is a semistructured 
interview scale with 18 items corresponding directly to the 18 
DSM-IV symptoms of ADHD. Each of the 2 project clinicians 
rated the clinical interviews and rating scales independently, 
and consensus ratings were subsequently reached. In cases of 
disagreement, a third rater (last author J.R.M.J.) was consulted.
Neurocognition
Performance-Based Tests
The Delay Frustration Test (DeFT) is a test of delay frustration 
in the form of a computerized, simple mathematics test. During 
the test, unpredictable and unsignalled delay periods occur, 
either of 3 to 10 seconds duration on 8 “distractor trials” or 20 
seconds on 8 “delay trials.” Delay frustration is indexed as the 
mean total duration (MTD) of responding per second of delay on 
the delay trials and is the product of the average response fre-
quency (i.e., number of responses per second) and the average 
duration of each response (i.e., total time of response per sec-
ond). A novel measure was also calculated: the inter-response 
SD in each delay trial (DEFT-SD), measured in milliseconds.
The Digit Span sub-test (Wechsler, 2008) was used to assess 
auditory-verbal working memory. This is a composite score con-
sisting of digit span forward, backward, and sequencing. Lastly, 
3 tests from the Cambridge Neuropsychological Test Automated 
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Battery (Sahakian and Owen, 1992) were used. The Rapid Visual 
Processing task (RVP) is designed primarily to assess sustained 
attention capacity; here, we report the number of “False Alarms” 
(RVP-FA) as a measure of response inhibition (Fan et al., 2014; 
Chamari et  al., 2016). Stockings of Cambridge (SOC) assesses 
spatial planning. Here, 3 parameters are reported: number of 
problems solved in the specified minimum number of moves 
(SOC-PS); the mean number of moves taken on the most difficult 
(5-move) problems; and mean initial thinking time on the most 
difficult problems (SOC-MIT). The spatial working memory task 
(SWM) (Robbins et  al., 1994) is based on a self-ordered search 
task. Here, 2 parameters are reported; strategy utilization, the 
number of search sequences starting with a novel box in the dif-
ficult problems (SWM-strat); and the total errors committed in 
the course of the test (SWM-TE).
Questionnaires
The Quick Delay Questionnaire (QDQ) (Clare et  al., 2010) is a 
10-item questionnaire intended to tap 2 dimensions of delay-
related behavior, each with 5-item scales: DA and delay dis-
counting. BRIEF-A (Roth et  al., 2005) is a 75-item self-report 
questionnaire concerning adults’ views of their EF in their eve-
ryday environment. It consists of 9 subscales; here, the Working 
Memory, Inhibit, and Plan/ Organize subscales are reported, as 
these can be considered the equivalent of the EFs we investi-
gated with performance-based measures.
Statistical Analyses
Data were analyzed with SPSS version 22. In case of missing data 
in the QDQ questionnaire (2 participants with ADHD and 2 healthy 
controls each missed 1 item), a score based on the rounded mean 
of the remaining scores for that subscale was imputed. All data 
were checked for skewness, normality, and outliers. Nonnormally 
distributed data were transformed (logarithmically or square root) 
to meet assumptions of normality and homogeneity of variance. 
Chi-square tests were used to assess differences between the 
patient and the control groups with regards to gender and paren-
tal education. Independent samples t tests were used to assess 
differences with regards to age, IQ, and ADHD symptomatology. 
Differences between the patient and the control groups at base-
line with regards to neurocognition were analyzed by a MANOVA 
for questionnaires and performance-based assessments sepa-
rately. In the case of a significant result, posthoc independent 
samples t tests were undertaken. Effect sizes were computed 
using Cohen’s d (d = M1 – M2/SDpooled). Differences in changes 
after treatment with medication between the patient and con-
trol groups were analyzed by a repeated-measures MANOVA for 
questionnaires and performance-based assessments separately. 
In the case of a significant finding, 2-way mixed ANOVAs were 
undertaken, with group as between-subjects factor and time as 
within-subjects factor, and effect sizes computed by partial eta 
squared (ηp
2). Further, within-group differences between baseline 
and follow-up performance were assessed by paired samples t 
tests. Spearman’s rho was used for correlational analyses. All sig-
nificance tests were conducted 2-tailed. Between-group analyses 
were re-run with estimated IQ as a covariate; any changes in sig-
nificance as a result of these analyses are reported.
Results
Participant Characteristics
There were no significant differences between the patient and 
control groups on parental educational level, age, or gender. 
However, the ADHD group had significantly lower estimated IQ 
and, as expected, significantly higher levels of ADHD symptom-
atology on both self-report and clinician-rated rating scales. On 
average, the patients were rated as having moderate to severe 
ADHD symptomatology on the Clinical Global Impression scale. 
A  total of 47.6% of the patient group screened positive on the 
clinical interview (MINI) as having at least one comorbid psy-
chiatric disorder (most commonly any anxiety disorder, N = 18, 
33.3%). See Table 1 for an overview of sample characteristics.
Cognitive and Motivational Deficits Prior to 
Treatment
PA multivariate ANOVA showed a significant effect of group 
for both self-report measures (V = .837, F(5,77) = 79.046, P < .0005) 
and performance-based tests (V = .344, F(9,74) = 4.311, P < .0005). 
Patients reported greater levels of DA and EF difficulties on all 
questionnaire measures, with very large effect sizes (QDQ DA 
t(82) = 10.186, P < .0005; delay discounting t(82) = 9.201, P < .0005; 
BRIEF-A inhibit scale t(81) = 12.486, P < .0005; BRIEF-A working 
memory scale t(81) = 16.740, P < .0005; and BRIEF-A planning/
organization scale t(81) = 15.372, P < .0005; see Table 2 for details).
Individuals with ADHD also demonstrated significant defi-
cits on tests of cognitive functioning, with the exception of the 
standard measure of delay frustration (DeFT-MTD: t(82) = -1.397, 
P = .166) and the mean initial thinking time on the SOC (SOC-
MIT: t(82) = 1.437, P = .155). Deficits were of large effect sizes for 
SWM total errors and digit span (SWM-TE t(82) = 4.533, P < .0005; 
digit span t(82) = 5.022, P < .0005). They were of moderate to large 
effect size for false alarms on the RVP, SWM strategy, and SOC 
number of problems solved (RVP-FA: t(82) = 2.688, P = .009; SWM-
strat: t(82) = 3.415, P = .001; SOC-PS t(82) = 2.468, P = .016) and 
of small to moderate sizes for the novel measure of the DeFT 
(DEFT-SD: t(82) = 2.016, P = .047). Finally, mean moves to solve 
5-move problems on the SOC just missed significance (SOC-MM 
t(82) = 1.983, P = .051).
When analyses were re-run with IQ as a covariate, signifi-
cance levels for differences between the groups were reduced 
and just missed significance for SWM-strat (P = .053) and became 
clearly insignificant for DEFT-SD, RVP-FA, SOC-PS, and SOC-MM 
(P > .19).
Exploratory Associations Between ADHD 
Symptomatology and Neurocognition
At baseline, in the patient group, 10 of 56 correlations between 
neurocognitive measures and ADHD symptomatology were sig-
nificant, all in the small to medium ranges. The QDQ subscales 
were significantly associated with all ADHD symptomatol-
ogy ratings (6 of 8 correlations), while only 1 of 12 correlations 
between BRIEF-A subscales and ADHD symptomatology was 
significant. Of the performance-based measures, 3 of 36 correla-
tions with ADHD symptomatology were significant. See Table 3 
for details.
Changes in Cognition After Methylphenidate 
Treatment
Repeated-measures MANOVA showed a significant group by 
time interaction for self-report measures (V = .242, F(1,73) = 23.294, 
P < .0005) but not for performance-based tests (V = .009, F(1,74) = .669, 
P = .416). Thus, 2-way mixed ANOVAs were undertaken only for 
the questionnaire measures. Significant interactions were seen 
for all questionnaire measures (QDQ DA F(1,74) = 10.854, P = .002 
and QDQ delay discounting F(1,74) = 6.937, P = .010; BRIEF-A inhibit 
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F(1,74) = 14.192, P < .0005; BRIEF-A working memory F(1,74) = 15.011, 
P < .0005; and BRIEF-A planning and organization F(1,74) = 16.888, 
P < .0005). See Table 2 for details.
Posthoc within-group analyses indicated that, compared 
with baseline, patients at follow-up reported significantly 
fewer difficulties on all questionnaire measures (all P < .0005). 
On cognitive tests, they improved significantly on SWM-TE 
(t(37) = 3.046, P < .004), digit span (t(37) = 2.159, P = .037), and 
SOC-PS (t(37) = 2.058, P = .047). Changes just missed significance 
for SWM-strat (t(37) = 1.804, P = .052) and were insignificant for 
RVP-FA, DEFT-SD, DEFT-MTD, SOC-MIT, and SOC-MM (all P > .10).
Associations Between Changes in ADHD Symptomatology and 
Neurocognition
Ratings of ADHD symptomatology decreased significantly after 
methylphenidate treatment in the patient group compared with 
the control group (all P < .004; see Table 2). Correlational analy-
ses were undertaken between changes in ADHD symptomatol-
ogy scores and the neurocognitive measures that had shown 
a significant change when controlling for retest effects in the 
patient group. Changes in QDQ scales showed significant, mod-
erate correlations (all rs .434 to .663) with changes in all ADHD 
symptom scales/subscales. Of the BRIEF-A subscales, Working 
Memory and Planning/Organization together showed 3 signifi-
cant associations with a symptomatology measure (self-rated 
ADHD symptoms and clinician rated inattention symptoms; rs . 
365 to .450). See Table 4 for details.
Discussion
The primary purpose of this study was to investigate whether 
DA and EF improved after 6 weeks of methylphenidate treat-
ment in a sample of initially stimulant medication-naïve adults 
with ADHD. When controlling for retest effects, we found no 
significant improvements in the ADHD group on any perfor-
mance-based test of DA or EF; in contrast, patients reported 
significant improvements in DA and EF as assessed with self-
report questionnaires.
Performance-Based Measures
The lack of improvement on performance-based measures is ini-
tially surprising, given significant, positive effects of methylphe-
nidate on response inhibition, working memory, and planning/
problem-solving in adults with ADHD reported in recent meta-
analyses/reviews (Chamberlain et  al., 2011; Tamminga et  al., 
2016). However, these mainly include acute studies, whereas 
the findings of prospective studies investigating the effect of 
at least 1 week of methylphenidate treatment in these cogni-
tive functions in adults with ADHD are mixed. This could stem 
from a number of methodological differences, such as whether 
patients were initially stimulant medication-naïve, final aver-
age dosage of medication, titration schedule, degree and type 
of comorbidity, and which measures were utilized to measure 
(the same) neurocognitive function. Of note, a study that utilized 
the same measure of response inhibition as this study (RVP-FA) 
did not find significant effects of methylphenidate (Ni et  al., 
2013); studies that utilized other measures have found a posi-
tive effect. Thus, for this particular measure, test insensitivity 
for (small) treatment effects may have been a factor.
Possibly the most important explanatory factor of previous 
mixed results is the extent to which retest effects were con-
trolled for. Thus, for working memory and planning, 3 previous 
studies have reported significant, positive effects but were all 
uncontrolled (Fallu et  al., 2006; Ginsberg et  al., 2012; Ni et  al., 
2013). Controlled children’s studies have found mixed effects 
of methylphenidate treatment for these functions (e.g., Coghill 
et al., 2007; Cristiana et al., 2017; Kortekaas-Rijlaarsdam et al., 
2017; Morell and Expósito, 2017). Two randomized control trial 
(RCT) studies indicate positive, significant effects of methyl-
phenidate for measures of response inhibition (Bouffard et al., 
2003; Boonstra et al., 2005), but these and 2 additional studies (Ni 
et al., 2013; Bron et al., 2014) also report nonsignificant findings. 
Table 1. Demographic and Clinical Characteristics of Adults With ADHD and Control Participants at Baseline
Patients
(n = 42)
Controls
(n = 42) P
Ages, y (SD) 26.9 (7.38) 26.7 (5.6) n.s.
No. (%) female 16 (34.0%) 18 (42.9%) n.s.
Parental education (1–3) (SD)a 1.93 (.52) 1.90 (.53) n.s.
Inter-session interval, weeks (SD) 6.7 (1.0) 6.7 (0.8) n.s.
Estimated IQ (SD)b 92.1 (13.1) 103.6 (10.88) <.0005
ADHD symptomatology 51.7 (9.5) 21.0 (9.0) <.0005
ASRS (SD)a 38.6 (7.6) 7.5 (5.2) <.0005
AISRS (SD)c 4.62 (0.69) 1.14 (0.42) <.0005
Clinical Global Impression scale (SD)
No. (%) psychiatric comorbidities (MINI) 22 (52.4%) 41 (97.6%) -
 0 20 (47.6%) 1 (2.4%) -
 ≥1 14 (33.3%) 0 (0.0%) -
 ≥2
Abbreviations: ASRS, Adult ADHD Self-Report Scale; AISRS, Adult ADHD Investigator Symptom Rating Scale; MINI, The Mini International Neuropsychiatric Interview; 
-, no statistical analysis undertaken.
Parental education was rated on a scale of 1 to 3 for the parent with the highest education, 1 indicates higher education.
The most common psychiatric disorders were: any anxiety disorder, n = 18; suicidality, n = 8 (no current suicidal ideation); dissocial personality 
disorder, n = 8; depression, n = 4. One control participant screened positive for depression. 
aOne missing data point.
bRange of estimated IQ at baseline for patients was 68 to 123; only 1 patient had an estimated IQ <70. 
cThe scale was used as an additional measure after commencement of the study, and there are missing data points for the first participants 
(baseline, n = 9; follow-up, n = 4).
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Lastly, our findings regarding the performance-based test of 
delay frustration are novel for an adult population but in line 
with one randomized, open controlled child study (Morell and 
Expósito, 2017).
The present study included a healthy control group, but 
interpretation of our null findings with respect to performance-
based measures should be considered in light of a number of 
methodological weaknesses. Our sample was relatively small, 
thus increasing likelihood of a type I error, and one-half of the 
patients screened positive for a secondary diagnosis other than 
ADHD (most commonly an affective disorder). However, domi-
nating psychiatric comorbidities (e.g., substance use disorders, 
severe depression) known to affect cognitive functioning were 
exclusion criteria in this study. Few prospective studies have 
investigated the impact of comorbid affective disorders on the 
effect of methylphenidate treatment on neurocognition, but 
comorbid depression may not impact methylphenidate effects 
(Riordan et al., 1999). Further, we investigated a relatively nar-
row range of neurocognitive functions with only 1 or 2 tests 
of each. A  broader battery of tests for specific neurocognitive 
functions and/or investigating a wider range of functions may 
have increased sensitivity to any effect of methylphenidate. 
Alternatively, the stability of these specific neurocognitive 
deficits, in conjunction with reduced ADHD symptomatology 
with medication, may be an indication of state independence 
(Gottesman and Gould, 2003; Braff et al., 2007), which could sup-
port previous evidence of cognitive biomarkers or endopheno-
types in ADHD (Pironti et al., 2014).
Self-Report Measures
There are to our knowledge no former studies of changes in 
self-reported DA after stimulant treatment. Our findings of 
medium- or large-sized effects for self-reported working memory, 
inhibition, and planning/organization extend previous findings of 
changes in self-reported EF after stimulant medication treatment, 
where retest effects were not controlled for (Biederman et  al., 
2015). While our use of a healthy control group allows some con-
trol for retest effects, a full RCT design would have allowed control 
of potential placebo effects and offered some degree of “structural 
equivalence” between our groups (Kabisch et al., 2011). This in turn 
would have allowed stronger conclusions concerning the effect 
of treatment on self-report measures, which may be more prone 
to reporter effects that performance-based measures (Sonuga-
Barke et al., 2008). However, a previous RCT found a positive, sig-
nificant effect of methylphenidate on the General Executive Index 
score from the BRIEF-A (Goodman et al., 2017). This supports the 
hypothesis that changes in self-reported neurocognition associ-
ated with methylphenidate treatment are not solely the result of 
nonoptimal methodology.
The difference in findings according to type of assessment, 
notwithstanding the limitations of our design, is potentially 
interesting. It is now fairly well accepted that there is little over-
lap between performance-based and self-report measures of 
cognition (Biederman et al., 2008; Toplak et al., 2013; Fuermaier 
et  al., 2015). While performance-based tasks are generally 
described as more objective and self-report as more ecologi-
cally valid (e.g., Roth et al., 2005), this dissociation may reflect 
that measures assess different underlying mental constructs 
and provide important and nonredundant information (Toplak 
et al., 2013). This has been argued to be the case especially for 
DA (Thorell et al., 2016).
Group Difference in EF and DA at Baseline
Pretreatment, stimulant medication-naïve ADHD patients 
reported very large, significant impairments in DA behaviors, 
Table 2. Cognitive Functioning of Adults With ADHD and Control Participants at Baseline and Follow-Up
Baseline Follow-up
Group x session 
interaction
Measure
Patients M 
(SD)
Controls M 
(SD) D
Patients M 
(SD)
Controls M 
(SD) d ηp
2
QDQ DA 3.34 (.76) 1.88 (.53) 2.23*** 2.54 (.75) 1.59 (.50) 1.49*** .128**
QDQ DDis 3.39 (.77) 2.05 (.53) 2.03*** 2.69 (.72) 1.82 (.60) 1.31*** .086*
BRIEF-A – inhib 17.71(3.62) 9.74 (1.83) 2.78*** 14.18 (3.70) 8.89 (1.27) 1.91*** .157*
BRIEF-A – WM 19.56 (3.03) 10.19 (1.97) 3.67*** 15.42 (4.09) 9.32 (1.34) 2.00*** .115*
BRIEF-A – plan 22.12 (3.02) 12.57 (2.63) 3.37*** 17.66 (4.30) 11.18 (1.20) 2.05***  .185***
DEFT - MTD (ms) 105 (145) 147 (194) - 74 (103) 226 (332) - .61* -
DEFT - SD (ms) 2083 (1616) 1460 (1049) .46 * 2148 (1593) 1408 (1347) .50 * -
RVP - FA 2.69 (3.09) 1.31 (1.24) .59 ** 1.66 (1.85) 0.87 (1.19) .51 * -
SWM strategy 30.64 (5.67) 26.38 (5.77) .74 * 28.03 (6.29) 23.82 (5.25) .73 ** -
SWM total error 20.52 (17.00) 7.71 (7.89) .97*** 13.61 (14.92) 4.79 (6.48) .77*** -
Digit span 23.00 (3.69) 27.12 (3.83) 1.09*** 24.47 (4.37) 28.74 (4.55) .96*** -
SOC – MIT 7849 (6037) 9843 (6664) - 9476 (8986) 9945 (5375) - -
SOC – PS 9.12 (1.70) 10.02 (1.66) .53 * 9.76 (1.73) 10.74 (1.45) .61 ** -
SOC – MM 6.38 (1.28) 5.87 (1.01) - 6.11 (1.25) 5.61 (0.94) .45 * -
ASRS 51.7 (9.5) 21.0 (9.0) 3.32*** 32.9 (12.4) 16.3 (9.6) 1.50*** .334***
AISRS 38.6 (7.6) 7.5 (5.2) 4.78*** 18.3 (9.3) 4.70 (4.9) 1.83*** .130**
Abbreviations: AISRS, Adult ADHD Investigator Symptom Rating Scale; ASRS, Adult ADHD Self-Report Scale; d, Cohen’s d; DEFT, Delay Frustration Test; DaV, Delay 
Aversion; DDis, Delay Discounting; inhib, inhibit subscale; MTD, Mean Total duration of pressing per second of delay; ηp2, partial eta squared; plan, planning/organiza-
tion subscale; QDQ, Quick Delay Questionnaire; RVP-FA, no. of false alarms; SWM strategy, number of search sequences starting with a novel box in the difficult prob-
lems; SWM-total error, total number of errors committed; SOC-MIT, mean initial thinking time on 5-move tasks; SOC-PS; problems solved in the specified minimum 
number of moves; SOC-MM, mean number of moves to solve 5-move tasks; WM, Working Memory subscale.
* P < .05 ** P < .01 *** P < .001.
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working memory, response inhibition, and planning. They also 
performed significantly worse on all performance-based tests 
of these domains, generally with moderate to large effect sizes. 
We failed, however, to find a significant between-group differ-
ence on the original measure of our performance-based test of 
DA (DEFT-MTD). Nonetheless, clinically it appeared that at least 
some of our patients responded to the unsignaled delay periods 
of the Delay Frustration Test to a greater extent than controls 
(e.g., with heightened levels of expressed frustration and physi-
cal activity). These types of responses have been hypothesized 
to result from underlying DA (Sonuga-Barke, 1994, 2005), which 
may reflect an attempt to attentionally disengage from the delay 
situation (Scime and Norvilitis, 2006; Cheyne et  al., 2009). We 
aimed to index this possible disengagement with a novel meas-
ure, the SD of inter-response interval (DEFT-SD), and found sig-
nificant group differences, which is the first time this has been 
demonstrated in an adult clinical sample.
Some of the specific neurocognitive deficits observed at 
baseline (i.e., response inhibition, strategy formation, planning, 
and DA) may have been partly mediated through lower IQ. There 
is disagreement as to whether studies of cognition in ADHD 
should control for IQ (e.g., Bridgett and Walker, 2006; Dennis 
et al., 2009). Our sample of patients had a mean estimated IQ of 
92.1 (SD = 13.1), lower than could be expected from a meta-anal-
ysis indicating an average decrement of 3 IQ points in adults 
with ADHD (Bridgett and Walker, 2006). This may partly reflect 
that we did not have exclusion criteria related to IQ and may 
lend weight to the argument that results should be presented 
with and without controlling for IQ (Bridgett and Walker, 2006) 
in this particular study.
Association Between Neurocognition and ADHD 
Symptomatology
Very few significant associations between performance-based 
neurocognitive measures and ADHD symptoms in patients at 
baseline were observed, even in exploratory analyses. These 
findings are in line with the few studies of stimulant medica-
tion-naïve individuals with ADHD that report these associations 
(e.g., Boonstra et al., 2005; Coghill et al., 2007; Bron et al., 2014). 
Further, these studies and the present study report a relative 
lack of association between changes in cognition and ADHD 
symptomatology after methylphenidate treatment. Together, 
these findings suggest a weak relationship between cognition 
and ADHD symptomatology. In particular, while methylpheni-
date clearly reduces severity of ADHD symptoms, it improves 
neurocognitive deficits to a lesser extent (e.g., Coghill et  al., 
2014). A possible explanation for these findings could again be 
that at least some cognitive functions are demonstrating state 
independence. Alternatively, it may be that differential dose-
response relationships exist for cognition and ADHD symptoms, 
respectively (Hale et al., 2011).
Exploratory analyses between self-report measures and 
ADHD symptomatology (both self-report and clinician-rated) 
showed a number of significant associations, most consistently 
with delay-related behaviors. This was the case both at baseline 
and with regards to changes after methylphenidate treatment. 
In contrast, very few associations between self-reported EF and 
ADHD symptomatology were significant. Pretreatment findings 
are in line with previous studies (Biederman et al., 2008, 2015). 
However, Biederman and colleagues (Biederman et al., 2008) also 
reported that improvements in self-reported EFs closely tracked 
improvement for ADHD symptoms after 6 weeks of treatment 
(formal associations between these variables were not reported). Ta
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Differences in study design/statistical methods may partly 
explain our differing findings.
This study has several limitations. Most importantly, a 
placebo condition was not included, and clinicians were not 
blinded to participant or medication status, thus weakening 
conclusions concerning whether self-reported changes after 
methylphenidate treatment can be regarded as relating to real 
changes in cognitive function rather than merely perceptions 
of improved functioning influenced by knowledge of treatment 
exposure. Further, we screened for psychiatric comorbidity 
using an instrument (MINI) that characterises disorder in binary 
terms rather than an instrument allowing dimensional ratings, 
and thus we could not investigate the effect of subthreshold 
symptoms of, for example, affectivity (Karalunas et  al., 2014). 
In light of these limitations, interpretations must be cautious. 
Nonetheless, our findings indicate that stimulant medication-
naïve adults with ADHD exhibited deficits in cognitive tests and 
self-reports of EF and DA. After 6 weeks of methylphenidate 
treatment, no improvements were seen in the ADHD group on 
performance-based measures of these functions; in contrast, 
patients reported significant improvements in these same 
functions. Associations between neurocognitive measures and 
ADHD symptomatology were found most consistently for self-
reported DA.
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